This commitment has attracted world-class research talent to Amgen and forged new ways to address the molecular roots of disease. Amgen helped to prove the potential of therapeutic proteins and antibodies, and our scientists have engineered entirely new modalities, such as peptibodies. These innovations and others under development give researchers multiple ways to target the defects that cause disease. They increase the odds of identifying safe and effective approaches to benefit patients who aren’t well-served by current therapies.
Amgen’s innovative approach to medical science and focus on discovering medicines to treat grievous diseases has shaped the culture and pride of the R&D organization. Our researchers delve as deep as the science leads them, both internally and through partnerships with other companies and universities. This approach has delivered important new therapies for hard-to-treat diseases, including cancer, kidney failure, blood disorders, and autoimmune and bone diseases. We are building on these successes with a drug pipeline that aims to give patients in need better options than they have now.
